Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recall DMAA Analog While FDA Evaluates Safety – CRN, Researchers

This article was originally published in The Tan Sheet

Executive Summary

An analog of the prohibited ingredient DMAA is found in products marketed as dietary supplements and poses a safety threat to consumers, according to research. The researchers say finding the ingredient in products available in the U.S. underscores the limits of FDA’s supplement regulations.

You may also be interested in...



SARMs Spells Latest 'Synthetic Steroids' FDA Finds In Supplements

FDA warns three US firms marketing products labeled as dietary supplements but containing selective androgen receptor modulators, SARMs, anabolic steroid-like ingredients that have the potential to increase the risk of heart attack and stroke and for which long-term effects are unknown.

DMAA Direct Seller Shut Down: Health And Wellness Industry News Roundup

ViviCeuticals closed in consent decree; Khan moves to top at NCNPR; and more news in brief.

FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door

USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel